2024
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
Kikuchi E, Gupta S, Loriot Y, Van Der Heijden M, Bedke J, Valderrama B, Flechon A, Petrylak D, De Santis M, Galsky M, Lee J, Swami U, Sridhar S, De Giorgi U, Wright P, Lu Y, Guan X, Dillon R, Homet Moreno B, Powles T. Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Journal Of Clinical Oncology 2024, 42: 108-108. DOI: 10.1200/jco.2024.42.23_suppl.108.Peer-Reviewed Original ResearchTime to pain progressionPlatinum-based chemotherapyPatient-reported outcomesBPI-SFPatients treated with platinum-based chemotherapyMedian time to pain progressionBrief Pain Inventory Short FormMetastatic urothelial cancerProgression-free survivalKaplan-Meier methodPhase 3 trialSurvival follow-upPatient-reported outcome assessmentsEnfortumab vedotinOverall survivalPain progressionTransient worseningUrothelial cancerPost-progressionQuality of Life QuestionnaireSevere painImproved survivalWorst painFollow-upWeek 4Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
Gupta S, Loriot Y, Van Der Heijden M, Bedke J, Valderrama B, Kikuchi E, Flechon A, Petrylak D, De Santis M, Galsky M, Lee J, Swami U, Sridhar S, De Giorgi U, Wright P, Lu Y, Guan X, Dillon R, Homet Moreno B, Powles T. Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Journal Of Clinical Oncology 2024, 42: 4502-4502. DOI: 10.1200/jco.2024.42.16_suppl.4502.Peer-Reviewed Original ResearchTime to pain progressionPlatinum-based chemotherapyPatient-reported outcomesBPI-SFMedian time to pain progressionPatients treated with platinum-based chemotherapyBrief Pain Inventory Short FormMetastatic urothelial cancerProgression-free survivalKaplan-Meier methodPhase 3 trialSurvival follow-upPatient-reported outcome assessmentsEnfortumab vedotinOverall survivalPain progressionTransient worseningUrothelial cancerQuality of Life QuestionnairePost-progressionSevere painImproved survivalWorst painFollow-upGlobal health status/qualityPatient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
Milowsky M, O'Donnell P, Hoimes C, Petrylak D, Flaig T, Moon H, Friedlander T, Mar N, McKay R, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, Bracarda S, Wright P, Hepp Z, Carret A, Yu Y, Dillon R, Kataria R, Beaumont J, Purnajo I, Rosenberg J. Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. Journal Of Clinical Oncology 2024, 42: 1403-1414. PMID: 38215355, PMCID: PMC11095879, DOI: 10.1200/jco.23.01547.Peer-Reviewed Original ResearchBPI-SF worst painPatient-reported outcomesEnfortumab vedotinEORTC QLQ-C30 quality of lifeBPI-SFQuality of lifeCisplatin-ineligibleUrothelial cancerWorst painTreatment armsBrief Pain Inventory Short FormAdvanced urothelial cancerPhase Ib/II trialBaseline to weekPatient-reported outcomes analysisAssociated with preservationTreatment of Cancer Quality of Life Questionnaire-Core QuestionnairePatients' quality of lifeSmall-to-moderate improvementsClinically Meaningful ImprovementsPatient-reported outcome instrumentsEuropean Organization for Research and TreatmentEORTC QLQ-C30First-lineClinical outcomes
2021
Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy
Curtis SA, Raisa BM, Roberts JD, Hendrickson JE, Starrels J, Lesley D, Michelle D, Daniel Z, Brandow AM. Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfusion And Apheresis Science 2021, 61: 103304. PMID: 34782244, PMCID: PMC9838733, DOI: 10.1016/j.transci.2021.103304.Peer-Reviewed Original ResearchConceptsChronic exchange transfusionsHealth care utilizationCare utilizationExchange transfusionPain impactDisease characteristicsChronic red blood cell transfusionsRed blood cell transfusionLower health care utilizationSickle Cell Disease PainExchange transfusion therapyAcute care utilizationBlood cell transfusionSimilar disease characteristicsPatient-reported outcomesLength of staySickle cell diseaseQuality of lifeCause admissionsCell transfusionNeuropathic painOpioid prescriptionsWorst painAcute painAdult patientsPrediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators
Schreiber KL, Zinboonyahgoon N, Flowers KM, Hruschak V, Fields KG, Patton ME, Schwartz E, Azizoddin D, Soens M, King T, Partridge A, Pusic A, Golshan M, Edwards RR. Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators. Annals Of Surgical Oncology 2021, 28: 5015-5038. PMID: 33452600, PMCID: PMC8280248, DOI: 10.1245/s10434-020-09479-2.Peer-Reviewed Original ResearchConceptsBody mass indexPain severitySensory disturbanceBreast surgeryProspective longitudinal observational cohort studyLongitudinal observational cohort studyHigher Body Mass IndexComprehensive preoperative assessmentFirst postsurgical yearPost-mastectomy painObservational cohort studyBaseline sleep disturbanceFunctional impactPostsurgical yearAxillary dissectionPain modulatorsPreoperative characteristicsWorst painCohort studyPain outcomesPain processingPain QuestionnaireSurgical variablesMass indexPain impact
2020
Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis
Pokrzywinski RM, Soliman AM, Snabes MC, Chen J, Taylor HS, Coyne KS. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis. Fertility And Sterility 2020, 115: 423-430. PMID: 33066973, DOI: 10.1016/j.fertnstert.2020.07.013.Peer-Reviewed Original ResearchConceptsSevere endometriosis-associated painEndometriosis-associated painNumerical rating scaleNonmenstrual pelvic painPelvic painWorst painMonth 3Rating ScalePain numerical rating scaleMeaningful changePremenopausal womenSevere endometriosisGlobal ImpressionClinical trialsMAIN OUTCOMEPainDysmenorrheaPhase IIIWomenElagolixResponsivenessTrialsPlaceboEndometriosisPatientsRelationships between chronic pain and mood symptoms among veterans with bipolar disorder
Travaglini L, Kuykendall L, Bennett M, Abel E, Lucksted A. Relationships between chronic pain and mood symptoms among veterans with bipolar disorder. Journal Of Affective Disorders 2020, 277: 765-771. PMID: 33065815, DOI: 10.1016/j.jad.2020.08.069.Peer-Reviewed Original ResearchConceptsChronic painQuality of lifeBipolar disorderMedical CenterPain experienceOutpatient mental health careVeterans Affairs Medical CenterVA Medical CenterChronic pain experienceMental health careUS military veteransManic mood statesWorst painPain managementBipolar depressionRetrospective studyManic episodesMood disordersMood symptomsOutpatient servicesPainUnipolar depressionPilot studyDisordersHealth care
2019
Evaluating Patients for Elective Outpatient Foot and Ankle Surgery: Insurance as a Predictor of Patient Outcomes
Bakhsh W, Childs S, Oh I, Flemister S, Baumhauer J, Ketz J. Evaluating Patients for Elective Outpatient Foot and Ankle Surgery: Insurance as a Predictor of Patient Outcomes. Foot & Ankle Specialist 2019, 12: 522-529. PMID: 30628476, DOI: 10.1177/1938640018823070.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesAnkle surgeryElective footNarcotic refillsPatient selectionRetrospective cohort studyRetrospective chart reviewCareful patient selectionElective surgical proceduresMultivariate regression modelingWorst painChart reviewCohort studyPostoperative outcomesPROMIS scoresTrauma patientsElective surgerySingle centerFunctional outcomeOutpatient footPatient outcomesSurgical proceduresPatientsLevel IIISurgery
2018
A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults With X‐Linked Hypophosphatemia: Week 24 Primary Analysis
Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen C, Theodore‐Oklota C, Mealiffe M, San Martin J, Carpenter TO, Investigators O. A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults With X‐Linked Hypophosphatemia: Week 24 Primary Analysis. Journal Of Bone And Mineral Research 2018, 33: 1383-1393. PMID: 29947083, DOI: 10.1002/jbmr.3475.Peer-Reviewed Original ResearchConceptsTreatment-related serious adverse eventsMean serum phosphate concentrationWOMAC physical function subscaleFibroblast growth factor 23Intact parathyroid hormoneSerious adverse eventsPhase 3 trialPhysical function subscaleChronic musculoskeletal painGrowth factor 23Serum phosphate concentrationRenal phosphate wastingHuman monoclonal antibodyLower limb deformitiesImportant medical needStiffness subscalePlacebo groupUrine calciumWorst painAdverse eventsWeek 24Dental abscessMusculoskeletal painFactor 23Function subscale
2013
A pilot trial of intravenous pamidronate for chronic low back pain
Pappagallo M, Breuer B, Lin H, Moberly J, Tai J, Noto C, Sanchez A, Manfredi P. A pilot trial of intravenous pamidronate for chronic low back pain. Pain 2013, 155: 108-117. PMID: 24060707, PMCID: PMC3947358, DOI: 10.1016/j.pain.2013.09.016.Peer-Reviewed Original ResearchConceptsChronic low back painLow back painPain scoresBack painDaily functioningAverage daily pain scoreDaily average pain scoreLeast-squares mean changeRandomized placebo-controlled studyPain-related interferenceDaily worst painDecreased pain intensityEscalating dose levelsDaily pain scoresPlacebo-controlled studyAverage pain scoreMetastatic bone diseaseProportion of respondentsPaget's disease of bonePain interferenceEvidence of degenerative diseaseClinically meaningful effectWorst painDisease of boneIntravenous pamidronate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply